# Nodal Downstaging of Esophageal Cancer After Neoadjuvant Therapy: A Cohort Study and Meta‐Analysis

## TL;DR

This study finds that patients with esophageal cancer who show no lymph node involvement after treatment have better survival than those with remaining cancer but worse than those who were never affected.

## Contribution

The study introduces cN+/ypN0 as a novel staging metric with distinct prognostic value in esophageal cancer after neoadjuvant therapy.

## Key findings

- cN+/ypN0 patients had survival comparable to natural N0 when assessed by clinical imagination.
- Pathological regression showed cN+/ypN0 had better overall survival than ypN+ but worse disease-free survival than natural N0.
- Meta-analysis confirmed the prognostic significance of cN+/ypN0 across multiple studies.

## Abstract

In esophageal cancer, the ypN0 status after induction therapy could be categorized into two primary groups: “natural N0” (cN0/ypN0) and “down‐staged N0” (cN+/ypN0). The assessment of cN status is typically based on clinical imagination or pathological regression. However, there is no standardized method for evaluating cN/ypN status. This study aims to investigate the prognosis of patients with cN+/ypN0 using both assessment methods through a cohort study and meta‐analysis.

A prospectively maintained database encompassing esophageal cancer patients undergoing induction therapy followed by radical esophagectomy was comprehensively reviewed. The prognostic significance of cN+/ypN0 across two evaluation methods was quantified. Additionally, a meta‐analysis using data from previous studies was conducted.

578 patients were identified from the cohort analysis, with 342 classified as ypN0 and 236 as ypN+. When evaluated with clinical imagination, patients with cN+/ypN0 had survival outcomes comparable to those with natural N0 but significantly better than those with ypN+ (p < 0.001). Using pathological nodal regression, cN+/ypN0 patients showed superior overall survival compared to ypN+ patients (p = 0.0043), although their disease‐free survival was notably inferior to that of natural N0 patients (p = 0.0088). A meta‐analysis of 20 previous studies confirmed the prognostic value of cN+/ypN0 status in both clinical imagination and pathological regression.

For esophageal cancer patients receiving neoadjuvant, cN+/ypN0 status, assessed through both clinical imagination and pathological regression, serves as a significant prognostic factor. It holds precedence over ypN+ yet falls short of the natural N0. The pre‐treatment categorizations warrant recognition as a novel and pertinent staging metric.